Use of Quantitative Real Time Polymerase Chain Reaction to Assess Gene Transcripts Associated with Antibody-Mediated Rejection of Kidney Transplants

Transplantation

Volumn 99, Issue 9, 2015, Pages 1981-1988

  Dominy, Katherine M ^a   Roufosse, Candice ^a,b   De Kort, Hanneke ^a   Willicombe, Michelle ^b   Brookes, Paul ^a   Behmoaras, Jacques V ^a   Petretto, Enrico G ^a   Galliford, Jack ^b   Choi, Peter ^b   Taube, David ^b   Cook, H Terence ^a,b   McLean, Adam G ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GENETIC MARKER; MESSENGER RNA; MYBL1 PROTEIN, HUMAN; ONCOPROTEIN; SH2D1B PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR;

ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE MARKER; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; GRAFT FAILURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; MYBL1 GENE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SH2D1B GENE; ADVERSE EFFECTS; BIOPSY; CASE CONTROL STUDY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETIC MARKER; GENETICS; GRAFT REJECTION; GRAFT SURVIVAL; HUMORAL IMMUNITY; IMMUNOLOGY; KAPLAN MEIER METHOD; KIDNEY TRANSPLANTATION; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME;

BIOPSY; CASE-CONTROL STUDIES; GENE EXPRESSION PROFILING; GENETIC MARKERS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNITY, HUMORAL; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 84944108632     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000621     Document Type: Article

References (28)

1. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol. 2007;18:1046.
2. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation. 2010;90:68.
3. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713.
4. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753.
5. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272.
6. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant. 2009;9:2312.
7. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant. 2010;10:1812.
8. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant. 2009;9:2561.
9. Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant. 2010;15:42.
10. Haas M. C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival. Clin Nephrol. 2011;75:271.
11. de Kort H, Willicombe M, Brookes P, et al. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant. 2013;13:485.
12. Haas M. Pathology of C4d-negative antibody-mediated rejection in renal allografts. Curr Opin Organ Transplant. 2013;18:319.
13. Sis B. Endothelial molecules decipher the mechanisms and functional pathways in antibody-mediated rejection. Hum Immunol. 2012;73:1218.
14. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant. 2011;11:56.
15. Allanach K, Mengel M, Einecke G, et al. Comparing microarray versus RT-PCR assessment of renal allograft biopsies: similar performance despite different dynamic ranges. Am J Transplant. 2008;8:1006.
16. Bustin SA, Mueller R. Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin Sci (Lond) 2005;109:365.
17. Iványi B, Fahmy H, Brown H, Szenohradszky P, Halloran PF, Solez K. Peritubular capillaries in chronic renal allograft rejection: a quantitative ultrastructural study. Hum Pathol. 2000;31:1129.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(Delta Delta C(T)) Method. Methods. 2001;25:402.
19. Schroeder A, Mueller O, Stocker S, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol. 2006;7:3.
20. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithmfor antibodymediated microcirculation inflammation in kidney transplants. Am J Transplant. 2012;12:1168.
21. Loupy A, Lefaucheur C, Vernerey D, et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol. 2014;25:2267.
22. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant. 2009;9:1826.
23. Lerut E, Naesens M, Kuypers DR, Vanrenterghem Y, Van Damme B. Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year. Transplantation. 2007;83:1416.
24. Kokko KE, Colvin RB. Below the waterline-The danger of de novo donorspecific HLA antibodies. Am J Transplant. 2012;12:1077.
25. Raghavaiah S, Stegall MD. New therapeutic approaches to antibodymediated rejection in renal transplantation. Clin Pharmacol Ther. 2011;90:310.
26. Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J AmSocNephrol. 1998;9:2129.
27. Hayde N, Broin P, Bao Y, et al. Increased intragraft rejection-associated gene transcripts in patients with donor-specific antibodies and normal biopsies. Kidney Int. 2014;86:600.
28. Danger R, Paul C, Giral M, et al. Expression of miR-142-5p in peripheral blood mononuclear cells from renal transplant patients with chronic antibody-mediated rejection. PLoS One. 2013;8:e60702.